BioKey's Strategic Positioning in U.S. Pharmaceutical Market Amid Global Tariff Shifts

ABVC BioPharma, Inc. has reaffirmed the strategic importance of its fully owned subsidiary, BioKey, Inc., as a U.S.-based pharmaceutical platform designed to address the growing global need for resilient and compliant drug development and production. Located in Fremont, California, BioKey's 28,000-square-foot FDA-compliant facility is positioned at the core of Silicon Valley's life sciences hub, offering a rare combination of physical manufacturing capacity and regulatory expertise under one roof.

The facility supports over 50 clinical trial batches annually and is equipped for both clinical supply and early commercial production. With the U.S. enacting tariffs of up to 40% on select pharmaceutical imports from Asia, companies like BioKey, with established U.S. infrastructure and compliance records, are at a strategic advantage. Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that BioKey's foresight in building its capabilities ahead of these policy shifts is now becoming a distinct competitive advantage.

BioKey serves as an operational bridge for Asian drug programs aiming to enter the U.S. market, offering FDA regulatory alignment, formulation transfer support, and access to a fully operational cGMP facility. This is particularly relevant as 72% of Asia-based pharmaceutical companies report increased difficulty accessing the U.S. market post-2024, according to IQVIA. BioKey's culturally fluent project management further facilitates bilingual technical communication and FDA meetings, addressing key challenges faced by Asian developers.

The global pharmaceutical contract development and manufacturing market, valued at $140 billion in 2024, is projected to grow significantly, underscoring the importance of BioKey's strategic positioning. With its lease set to expire in 2026 and options to extend, BioKey plans to continue operations at its current facility, reinforcing its commitment to providing a trusted, localized solution in the evolving global pharmaceutical landscape.